11.00–11.05Welcome to HIV Glasgow Day Four

11.05–12.45New perspectives on ART

11.05–11.20Two-drug regimens
Pedro Cahn, Buenos Aires, Argentina

11.20–11.35Long acting injectables for ART
Marta Boffito, London, UK

11.35–11.50Novel ART compounds
Chloe Orkin, Queen Mary University, London, UK

11.50–11.58Islatravir in combination with doravirine maintains HIV-1 viral suppression
through 96 weeks
Jean-Michel Molina, Saint-Louis and Lariboisière Hospitals and University
of Paris, Paris, France

11.58–12.06Safety and efficacy of cabotegravir + rilpivirine long-acting with and without
oral lead-in: FLAIR Week 124 results
Chloe Orkin, Queen Mary University, London, UK

12.06–12.14Single doses of MK-8507, a novel HIV-1 NNRTI, reduced HIV viral load for at least
a week
Wendy Ankrom, Clinical Research, Merck Sharp & Dohme, West Point, PA, USA

12.14–12.45Q & A

12.45–13.00Break

13.00–14.15Industry Symposium

14.15–14.45Break

14.45–16.00HIV, ART and COVID-19: interplay and interactions
In collaboration with the British HIV Association (BHIVA)

14.45–14.50Welcome & introductions and brief summary of BHIVA’s COVID-19 activities
Caroline Sabin and Laura Waters

14.50–15.05UK community survey results
Alex Sparrowhawk, Chair of UK Community Advisory Board (UK-CAB), London, UK

15.05–15.20Are antiretrovirals active against SARS-COV-2?
Andrew Owen, University of Liverpool, Liverpool, UK

15.20–15.35COVID-19 testing, transmission and immunity
Muge Cevik, University of Aberdeen, Aberdeen, UK

15.35–15.43Outcomes of COVID-19 related hospitalisation among people with HIV in the
United Kingdom and comparison to those without HIV
Anna Maria Geretti, Institute of Infection, University of Liverpool, Liverpool, UK

15.43–15.45Closing summary and future plans
Caroline Sabin

15.45–16.00Panel Discussion and Q & A 
All

16.00–16.15Break

16.15–17.00Cure Update

16.15–16.30Progress towards developing an effective cure of HIV infection
Steven Deeks, University of California – San Francisco, San Francisco, CA, USA

16.30–16.45HBV Cure
Mala Maini, London, UK

16.45–17.00Q & A

17.00–17.15Break

17.15–18.15Emerging Topics in HIV and COVID-19

17.15–17.28Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing
a TAF-based regimen (TBR) in maintaining virologic suppression through
96 weeks (TANGO study)
Stéphane De Wit, CHU St-Pierre, Brussels, Belgium

17.28–17.41A combination of viral and participant factors influence virologic outcome to
long-acting cabotegravir and rilpivirine: multivariable and baseline factor
analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies
David Margolis Clinical Development, ViiV Healthcare, Research Triangle
Park, NC, USA

17.41–17.54Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate
vaccine, in adults infected with HIV: a phase III trial
Olayemi Osiyemi Infectious Diseases, Triple O Research Institute,
West Palm Beach, FL, USA

17.54–18.07SARS-CoV-2 infection in pregnancy and newborn in a Spanish multicentric
cohort (GESNEO-COVID)
Itziar Carrasco Paediatrics, Hospital General Universitario Gregorio
Marañón, Madrid, Spain

18.07–18.15Congress Closing Remarks
Andrew Phillips, London, UK
Brian West, Edinburgh, Scotland